Material and Methods
The detailed administration of the trial was purposely designed to replicate closely that of Thomson and Guest (1963) control group who died suddenly) completed the trial. All showed clinical stigmata typical of the sex-linked recessive Duchenne type of dystrophy and all had grossly increased serum creatine kinase activity (100 to 800 units). This enzyme was chosen to monitor the biochemical progress of the disease, as it has been shown (Pearce, Pennington, and Walton, 1964b) Hill (1963) . In every other respect, and particularly in relation to periods of compulsory bedrest, the patients in the two groups were treated identically. The observer assessing muscle strength was totally unaware of the group to which each patient belonged. Drug administration was planned and carried out by an independent observer who did not participate in the pre-and posttreatment assessments. Serum creatine kinase estimations were carried out as described by Pearce, Pennington, and Walton (1964a) . The results are expressed as pmoles of creatine formed per ml. of serum per hour at 370 C. Muscle power was assessed by methods essentially similar to those employed by Barwick et al. (1963) . Ergometric measurements were made using a simple spring balance during maximal voluntary contraction of four muscle groups on each side-namely, the flexors and extensors of the elbow and the flexors and extensors of the knee; three separate measurements of the strength of each muscle group were made at each examination, the result recorded in pounds being the average of all three.
The final figure recorded at each examination was the sum of the means obtained for each group. Power was also assessed according to the Medical Research Council (1943) scale in the flexors and extensors of the wrist-and elbow-joints, the abductors and flexors of the shoulder, the extensors of the knee, and the dorsiflexors of the ankle. A numerical recording (0 to 5) was obtained for each muscle tested, and the total " score " obtained at each examination was taken as the sum of the scores of the individual muscles tested.
Details of Treatment
Each child was put to bed and basal assessments were made of serum creatine kinase (C.K.) and of muscle strength by spring balance and by M.R.C. (1943) grading. The Laevadosin group of patients then received a five-day intra-venous infusion of the drug in saline. The doses given were 5, 10, 15, 20, and 25 ml. of Laevadosin on successive days. After the infusion the child was allowed up for 28 to 30 days and during this time received 5 ml. of Laevadosin daily intramuscularly. This month concluded, he was returned to bed and was given a further five-day intravenous infusion of Laevadosin, containing 10, 20, 30, 50, and 75 ml. of solution. After two to four days out of bed, so that muscular stiffness and the effects of any local bruising had worn off, muscle strength was again tested and recorded by the same observer.
The control group were treated in an identical fashion with bed-rest and muscle-strength measurements performed at the same time, but they received calcium lactate 300 mg. three times daily by mouth throughout the period of treatment. The patients were assessed in pairs, and, in case local bruising might reveal which patient had received the intravenous therapy, both children had their arms covered with dressings.
Results
Tables I and II show the results of testing muscle strength before and after treatment in the two groups of patients. The Laevadosin ( -6 .5%) and controls (-0.7 %) is not statistically significant (Table III) . The results of M.R.C. grading measurements (Table IV) were similar to the muscle springbalance analysis, the mean percentage improvements being Laevadosin -2.3 and controls -0.1. These changes are not significant.
Serial estimations of serum creatine kinase levels were performed on all patients. These were carried out before treatment; on days 3, 5, and 7, covering the first intravenous infusion; weekly during the month of intramuscular injections; and on days 34, 35, 37, and 39-that is, before, during, and after the second intravenous infusion. Creatine kinase levels were measured at the same time on patients in the control group. For convenience the average activities of this enzyme at different stages of the trial are grouped together in Table V . The changes from the initial level occurring in the treatment and control groups are shown in One child in the Laevadosin-treated group had an initial C.K. level of 700 units as compared with the next highest initial level in the whole series of 340 units; in his case there was a striking fall in activity during treatment and the enzyme has not subsequently increased to a figure comparable to the initial reading. If this one child with the highest initial level is excluded, each of the figures in the mean C.K. column (Table VI) becomes greater than the corresponding control figure-that is, unfavourable to Laevadosin (Table VII) . Thus while at first sight the figures given in Table VI suggest that a greater fall occurred in C.K. activity during treatment in patients receiving Laevadosin, it will be seen from Table VII that this impression was false, being almost wholly due to the fall which occurred in a single case. When the results for other individual patients are closely inspected there is a general trend in both control and treatment groups for the serum C.K. level to fall during the period of bed-rest and to rise subsequent to the mobilization of the patient. By the inspection of the individual differences it is clear that there is no statistically significant difference between the two groups of patients at any time. This could indicate that serum C.K. is too variable a measurement to demonstrate difference between the treatments, but it could also be interpreted as showing that Laevadosin produces no more diminution in serum enzymes-that is, improvement in the dystrophic process-than does the placebo-control therapy.
The results of the muscle-strength testing by spring balance (Table I ) and by M.R.C. grading (Table II) have been subjected to statistical analysis (Tables III and IV) . Each analysis is on a " within patient " basis. Absolute differences (not tabulated) and percentage differences have been calculated and the results are almost identical. The patients receiving Laevadosin deteriorated slightly; the controls remained unchanged, but the differences were not significant.
We have conclusively demonstrated that Laevadosin is not better than a placebo when administered in this dosage over a period of six weeks as recommended by Thomson and Guest (1963) . This does not imply that the drug is without value. To establish the value of the preparation it is necessary to carry out a more prolonged trial, incorporating both longer periods of treatment and longer periods of follow-up. Such a trial is now in progress in this centre and will be the subject of a further report. Until this or a similar adequately controlled assessment has been reported we believe that there is no clinical indication for the routine administration of this nucleoside-nucleotide mixture to patients with muscular dystrophy.
Summary
Laevadosin, a mixture of nucleotides and nucleosides, when administered to patients with the Duchenne type of muscular dystrophy over a six-week period did not produce any observable benefits when compared with a placebo. The results were based on objective assessment of alterations in muscle power and changes in serum creatine kinase levels. The drug may be found to be of value after a more prolonged period of treatment and follow-up, but until the results of such an extended trial are known the routine administration of this remedy to patients with muscular dystrophy is not recommended.
